Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 17/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.55 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.55 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2821932 | 0.88 | DHODH (0.53) | DHODHNPC1RAB9APOLBMAPT | |
| SCHEMBL2402968 | 0.85 | BRAF (0.53) | DHODHNPC1RAB9APOLBMAPT | |
| SCHEMBL19626177 | 0.79 | AKR1C3 (0.67) | DHODHMAPT | |
| SCHEMBL18796169 | 0.79 | NPC1 (0.51) | NPC1RAB9APOLBMAPTSMN1; SMN2 | |
| SCHEMBL468722 | 0.79 | DHODH (1.00) | DHODH | |
| SCHEMBL468404 | 0.78 | DHODH (1.00) | DHODH | |
| SCHEMBL4218152 | 0.78 | KDR (0.50) | DHODHNPC1RAB9APOLBMAPT | |
| SCHEMBL2821937 | 0.78 | NPC1 (0.43) | DHODHNPC1RAB9APOLBMAPT | |
| SCHEMBL468565 | 0.77 | DHODH (0.79) | DHODH | |
| SCHEMBL29101218 | 0.77 | MAPT (0.58) | NPC1RAB9APOLBMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389197-B1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | ALMIRALL SA (ES) | 2014-06-18 | — | — | EP | claimed |
| US-20140005178-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2014-01-02 | — | — | US | claimed |
| EP-2178840-B1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL SA (ES) | 2011-12-14 | — | — | EP | claimed |
| EP-2389197-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | Almirall S.A. (ES) | 2011-11-30 | — | — | EP | claimed |
| US-20110280831-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2011-11-17 | — | — | US | claimed |
| US-20110253957-A1 | Compliant motion distribution system | FLEXSYS, INC. | 2011-10-20 | — | — | US | claimed |
| US-20110212945-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2011-09-01 | — | — | US | claimed |
| WO-2010083975-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2010-07-29 | — | — | WO | claimed |
| EP-2210615-A1 | Combinations comprising methotrexate and DHODH inhibitors | Almirall, S.A. (ES) | 2010-07-28 | — | — | EP | claimed |
| EP-2100881-A1 | Pyrimidyl- or pyridinylaminobenzoic acid derivatives | Laboratorios Almirall, S.A. (ES) | 2009-09-16 | — | — | EP | claimed |
| EP-2389197-B1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | ALMIRALL SA (ES) | 2014-06-18 | — | — | EP | disclosed |
| US-20140005178-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2014-01-02 | — | — | US | disclosed |
| US-8536165-B2 | Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors | ALMIRALL, S.A. (ES) | 2013-09-17 | — | — | US | disclosed |
| US-8536165-B2 | Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors | ALMIRALL, S.A. (ES) | 2013-09-17 | — | — | US | disclosed |
| WO-2012052180-A1 | COMBINATIONS COMPRISING DHODH INHIBITORS AND COX INHIBITORS | ALMIRALL, S.A. (ES) | 2012-04-26 | — | — | WO | disclosed |
| EP-2178840-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | Almirall, S.A. (ES) | 2010-04-28 | — | — | EP | disclosed |
| EP-2100881-A1 | Pyrimidyl- or pyridinylaminobenzoic acid derivatives | Laboratorios Almirall, S.A. (ES) | 2009-09-16 | — | — | EP | disclosed |
| EP-2100881-A1 | Pyrimidyl- or pyridinylaminobenzoic acid derivatives | Laboratorios Almirall, S.A. (ES) | 2009-09-16 | — | — | EP | disclosed |
| WO-2009021696-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021696-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280831-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | DHODH, CBR3, HRH4 | DHODH 1/4885NPC1 2240/4885RAB9A 2042/4885 |
| US-20140005178-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | DHODH, DPYD, DLD | DHODH 1/4885NPC1 1549/4885RAB9A 1688/4885 |
| US-20110212945-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | DHODH, DPYD, DLD | DHODH 1/4885NPC1 1549/4885RAB9A 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.